VGX™ Pharmaceuticals

HIV Drug Market

Major Global Health Threat: 40 Million People Worldwide

1 Million HIV-Positive Individuals and 60,000 New Infections Each Year in the US

2003 Total US Sales of HIV Drugs was Approximately $3.2 Billion

Combinations of 3+ Drugs Required for Sufficient Efficacy

30 - 50 % of Patients Develop Resistance to One or More Drug Combinations

New Drugs with Different Mechanisms of Action are Needed!

HIV Reproduction Cycle

	HIV fuses with host cell
	RNA converts to DNA
	DNA transported to nucleus
	DNA inserts into human chromosome
	Viral RNA and proteins are produced
	Virus assembles at membrane
	New virus leaves cell

PICTOVIR™ – First in New Class of HIV Drugs

Current HIV Drug Approaches
	Target RT, Protease and Fusion
	Each of these approaches attack the virus
	Virus responds by mutating
	Limits long-term use
PICTOVIR™
	Targets Pre-Integration ComplexTranslocation (PICT) mechanism
	PICTOVIR™ blocks translocation mechanism (Host) instead of attacking the virus
	Significantly reduces mutation effect of virus
	Better suited for long-term use

PICT Mechanism of Action

HIV Pre-Integration Complex (PIC) must translocate to nucleus for viral replication

PIC hijacks cell’s own transport mechanism (mov34/GRII pathway)

PICTOVIR™ blocks this mechanism, thereby stopping the reproduction cycle

Strong IP Protects Whole Class of New Anti-HIV Drugs

Potential Advantages of PICTOVIR™ As An HIV Drug

Safe and Well Tolerated

Accelerated Regulatory Approval Pathway

The First in a Novel Class of HIV Drugs (PICT Inhibitor)

Orally Active Drug

Significantly Reduces Viral Resistance Allowing for Long-Term Use of PICTOVIR™

Strong Clinical Partnerships with the NIH and AACTG